全球糖尿病前期市場研究報告 - 產業分析、規模、佔有率、成長、趨勢和預測 2025 年至 2033 年

全球糖尿病前期市場規模預計將從 2024 年的 2.4076 億美元成長到 2033 年的 4.7055 億美元，在 2026 年至 2033 年的預測期內呈現 7.73% 的強勁年複合成長率(CAGR)。

隨著糖尿病前期盛行率的不斷上升以及人們對其健康影響的認知不斷提高，全球糖尿病前期市場有望實現大幅成長。糖尿病前期的特徵是血糖值升高，但不足以被歸類為糖尿病，這種疾病影響著全世界數百萬人。隨著醫療保健提供者和患者認知到早期干預對於防止進展為 2 型糖尿病的重要性，對糖尿病前期篩檢、診斷工具和管理解決方案的需求預計將大幅上升，從而促進這一關鍵市場的創新和投資。

此外，數位健康技術和個人化醫療的進步預計將進​​一步推動糖尿病前期市場的發展。行動健康應用程式、穿戴式裝置和遠距醫療平台的開發使個人能夠監測血糖水平、追蹤生活方式的變化並獲得醫療保健專業人員的個人化指導。此外，人們越來越重視生活方式改變計劃，包括改變飲食和體能鍛煉，這推動了對綜合管理解決方案的需求，使個人能夠掌控自己的健康。隨著醫療保健領域的不斷發展，糖尿病前期解決方案市場對滿足不同患者需求的創新產品和服務的需求可能會激增。

此外，對法規遵從性和公共衛生措施的日益關注預計將影響糖尿病前期市場的未來。隨著政府和衛生組織實施旨在提高意識和促進預防措施的計劃，對糖尿病前期篩檢和管理解決方案的需求將持續上升。醫療保健提供者、技術開發商和監管機構之間的協作努力對於推動這些進步至關重要，確保糖尿病前期市場能夠滿足患者和醫療保健系統不斷變化的需求。

我們的報告經過精心製作，為客戶提供有關各個行業和市場的全面且可操作的見解。每份報告都包含幾個關鍵部分，以確保徹底了解市場格局：

市場概覽：市場的詳細介紹，包括定義、分類和行業現狀概述。

市場動態：深入分析影響市場成長的關鍵促進因素、限制因素、機會與挑戰。本節探討技術進步、監管變化和新興趨勢等因素。

細分分析：根據產品類型、應用、最終用戶和地理位置等標準將市場細分為不同的細分市場。該分析強調了每個部分的表現和潛力。

競爭格局：對主要市場參與者的全面評估，包括其市場佔有率、產品組合、策略舉措和財務表現。本節深入介紹領先公司的競爭動態和關鍵策略。

市場預測：根據歷史資料和當前市場狀況，預測特定時期內的市場規模和成長趨勢。這包括定量分析和圖形表示來說明未來的市場軌跡。

區域分析：評估不同地理區域的市場表現，確定關鍵市場和區域趨勢。這有助於了解區域市場動態和機會。

新興趨勢與機會：識別當前和新興的市場趨勢、技術創新和潛在投資領域。本節提供未來市場發展和成長前景的見解。

目錄

第 1 章：前言

• 報告描述
  • 客觀的
  • 目標受眾
  • 獨特銷售主張 (USP) 產品
• 研究範圍
• 研究方法
  • 市場研究流程
  • 市場研究方法

第 2 章：執行摘要

• 市場亮點
• 全球市場概況

第 3 章：糖尿病前期產業分析

• 簡介 - 市場動態
• 市場促進因素
• 市場限制
• 機會
• 產業趨勢
• 波特五力分析
• 市場吸引力分析
  • 按藥品類別進行市場吸引力分析
  • 按年齡分析市場吸引力
  • 市場吸引力分析：按地區

第4章：價值鏈分析

• 價值鏈分析
• 原料分析
  • 原料清單
  • 原料製造商清單
  • 主要原物料價格走勢
• 潛在買家名單
• 行銷管道
  • 直效行銷
  • 間接行銷
  • 行銷通路發展趨勢

第 5 章：全球糖尿病前期市場分析：依藥物類別

• 按藥物類別概述
• 歷史和預測數據
• 按藥物類別分析
• 雙胍類
• 噻唑烷二酮類
• 胰高血糖素樣胜肽-1 激動劑 (GLP-1)
• SGLT2 抑制劑
• DPP-4 抑制劑
• 其他

第 6 章：全球糖尿病前期市場分析：依年齡層

• 年齡層概覽
• 歷史和預測數據
• 年齡層分析
• 兒童（12-18歲）
• 成人（18-49 歲）
• 老年人（50 歲以上）

第 7 章：全球糖尿病前期市場分析：按地區分類

• 區域展望
• 介紹
• 北美銷售分析
  • 概述、歷史和預測數據銷售分析
  • 北美各細分市場銷售分析
  • 北美各國銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概述、歷史和預測數據銷售分析
  • 歐洲各細分市場銷售分析
  • 歐洲各國銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 義大利銷售分析
  • 俄羅斯銷售分析
  • 歐洲其他地區銷售分析
• 亞太地區銷售分析
  • 概述、歷史和預測數據銷售分析
  • 亞太地區分部銷售分析
  • 亞太地區國家銷售分析
  • 中國銷售分析
  • 印度銷售分析
  • 日本銷售分析
  • 韓國銷售分析
  • 澳洲銷售分析
  • 東南亞銷售分析
  • 亞太地區其他地區銷售分析
• 拉丁美洲銷售分析
  • 概述、歷史和預測數據銷售分析
  • 拉丁美洲各細分市場銷售分析
  • 拉丁美洲各國銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利銷售分析
  • 拉丁美洲其他地區銷售分析
• 中東非洲銷售分析
  • 概述、歷史和預測數據銷售分析
  • 中東非洲各細分市場銷售分析
  • 中東非洲國家銷售分析
  • 沙烏地阿拉伯銷售分析
  • 阿拉伯聯合大公國銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 中東和非洲其他地區銷售分析

第 8 章：糖尿病前期公司的競爭格局

• 糖尿病前期市場競爭
• 夥伴關係/合作/協議
• 合併與收購
• 新產品發布
• 其他進展

第9章：公司簡介

• 頂級公司市佔率分析
• 市場集中度
• Novo Nordisk
• 公司概況
• 公司收入
• 產品
• 最新動態
• Valbiotis
• 公司概況
• 公司收入
• 產品
• 最新動態
• Resverlogix
• 公司概況
• 公司收入
• 產品
• 最新動態
• Caelus Health
• 公司概況
• 公司收入
• 產品
• 最新動態
• SciMar
• 公司概況
• 公司收入
• 產品
• 最新動態
• Boston Therapeutics
• 公司概況
• 公司收入
• 產品
• 最新動態
• Aphaia Pharma
• 公司概況
• 公司收入
• 產品
• 最新動態
• AstraZeneca
• 公司概況
• 公司收入
• 產品
• 最新動態
• Bristol-Myers Squibb
• 公司概況
• 公司收入
• 產品
• 最新動態

注意 - 在公司簡介中，財務細節和近期發展取決於可用性，對於私人公司，可能不予涵蓋

Global Prediabetes Market size is anticipated to grow from USD 240.76 Million in 2024 to USD 470.55 Million by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 7.73% during the forecast period of 2026 to 2033.

The global prediabetes market is poised for significant growth, driven by the increasing prevalence of prediabetes and the rising awareness of its health implications. Prediabetes, characterized by elevated blood sugar levels that are not yet high enough to be classified as diabetes, affects millions of individuals worldwide. As healthcare providers and patients recognize the importance of early intervention to prevent the progression to type 2 diabetes, the demand for screening, diagnostic tools, and management solutions for prediabetes is expected to rise substantially, fostering innovation and investment in this critical market.

Moreover, advancements in digital health technologies and personalized medicine are anticipated to further boost the prediabetes market. The development of mobile health applications, wearable devices, and telehealth platforms enables individuals to monitor their blood sugar levels, track lifestyle changes, and receive personalized guidance from healthcare professionals. Additionally, the growing emphasis on lifestyle modification programs, including dietary changes and physical activity, is driving the demand for comprehensive management solutions that empower individuals to take control of their health. As the healthcare landscape continues to evolve, the market for prediabetes solutions is likely to witness a surge in demand for innovative products and services that cater to diverse patient needs.

In addition, the increasing focus on regulatory compliance and public health initiatives is expected to shape the future of the prediabetes market. As governments and health organizations implement programs aimed at raising awareness and promoting preventive measures, the demand for prediabetes screening and management solutions will continue to rise. Collaborative efforts between healthcare providers, technology developers, and regulatory bodies will be essential in driving these advancements, ensuring that the prediabetes market remains responsive to the evolving needs of patients and healthcare systems.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Drug Class

• Diguanide
• Thiazolidinediones
• Glucagon-Like Peptide-1 Agonists (GLP-1)
• SGLT2 Inhibitors
• DPP-4 Inhibitors
• Others

By Age Group

• Children (12-18 Years)
• Adults (18-49)
• Elderly (50+)
• COMPANIES PROFILED
• Novo Nordisk
• Valbiotis
• RESVERLOGIX
• Caelus Health
• SciMar
• Boston Therapeutics
• Aphaia Pharma
• AstraZeneca
• Bristol-Myers Squibb
• The above list can be customized.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . PREDIABETES INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class
  • 3.7.2 Market Attractiveness Analysis By Age Group
  • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PREDIABETES MARKET ANALYSIS BY DRUG CLASS

• 5.1 Overview by Drug Class
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Drug Class
• 5.4 Diguanide Historic and Forecast Sales by Regions
• 5.5 Thiazolidinediones Historic and Forecast Sales by Regions
• 5.6 Glucagon-Like Peptide-1 Agonists (GLP-1) Historic and Forecast Sales by Regions
• 5.7 SGLT2 Inhibitors Historic and Forecast Sales by Regions
• 5.8 DPP-4 Inhibitors Historic and Forecast Sales by Regions
• 5.9 Others Historic and Forecast Sales by Regions

6 . GLOBAL PREDIABETES MARKET ANALYSIS BY AGE GROUP

• 6.1 Overview by Age Group
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Age Group
• 6.4 Children (12-18 Years) Historic and Forecast Sales by Regions
• 6.5 Adults (18-49) Historic and Forecast Sales by Regions
• 6.6 Elderly (50+) Historic and Forecast Sales by Regions

7 . GLOBAL PREDIABETES MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast DataSales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast DataSales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast DataSales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. South East Asia Sales Analysis
  • 7.5.10. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast DataSales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast DataSales Analysis
  • 7.7.2. Middle East Africa by Segment Sales Analysis
  • 7.7.3. Middle East Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE PREDIABETES COMPANIES

• 8.1. Prediabetes Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF PREDIABETES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Novo Nordisk
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Valbiotis
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. Resverlogix
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. Caelus Health
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. SciMar
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. Boston Therapeutics
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Aphaia Pharma
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. AstraZeneca
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments
• 9.11. Bristol-Myers Squibb
  • 9.11.1. Company Overview
  • 9.11.2. Company Revenue
  • 9.11.3. Products
  • 9.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Drug Class (USD MN)
• Diguanide Market Sales by Geography (USD MN)
• Thiazolidinediones Market Sales by Geography (USD MN)
• Glucagon-Like Peptide-1 Agonists (GLP-1) Market Sales by Geography (USD MN)
• SGLT2 Inhibitors Market Sales by Geography (USD MN)
• DPP-4 Inhibitors Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis Market by Age Group (USD MN)
• Children (12-18 Years) Market Sales by Geography (USD MN)
• Adults (18-49) Market Sales by Geography (USD MN)
• Elderly (50+) Market Sales by Geography (USD MN)
• Global Prediabetes Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Prediabetes Report
• Market Research Process
• Market Research Methodology
• Global Prediabetes Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Drug Class
• Market Attractiveness Analysis by Age Group
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Drug Class (USD MN)
• Diguanide Market Sales by Geography (USD MN)
• Thiazolidinediones Market Sales by Geography (USD MN)
• Glucagon-Like Peptide-1 Agonists (GLP-1) Market Sales by Geography (USD MN)
• SGLT2 Inhibitors Market Sales by Geography (USD MN)
• DPP-4 Inhibitors Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Age Group (USD MN)
• Children (12-18 Years) Market Sales by Geography (USD MN)
• Adults (18-49) Market Sales by Geography (USD MN)
• Elderly (50+) Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.